#ViiV Healthcare

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.

After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.

4% of total U.S. AIDS philanthropy directly addresses African Americans. Plus: Meet the top five funders helping BIPOC communities.

A global study examined how outcomes improve when physicians engage their HIV-positive patients in joint decision-making.

A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.

“As Much As I Can” returns with a new format but the same powerful messages.

Who got what and why? NMAC’s Paul Kawata addresses criticism and breaks down the data.

The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

“As Much As I Can” debuted in the South. This week, it opens in Harlem, New York.

“As Much As I Can” is part of the Accelerate! initiative. Tickets are free!

ViiV Healthcare’s four-year, $10 million ’Accelerate!’ initiative aims to reduce the HIV epidemic among black men who have sex with men (MSM)...

ViiV Healthcare has given about $ 6 million to 99 projects in 26 countries to improve the health of women, children and families affected by H...